David Hasselbacher, MD
Pulmonary Disease · Louisville, KYNPI 1073638482
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Boehringer Ingelheim at 54.8% of the total.
Across 240 payments — averaging $63.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- AstraZeneca$2K
- GSK$1K
- Insmed, Inc.$461
- Boehringer Ingelheim International GmbH$430
- Grifols USA, LLC$321
- plus $3K from 30 others
Across 1 payment — averaging $9199.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$9K
What the payments were for
- Consulting fees$6,91345%
- Food & beverage$8,23454%
- Education$2101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 46 | $8,414 |
| AstraZeneca | 38 | $1,873 |
| GSK | 40 | $1,193 |
| Insmed, Inc. | 15 | $461 |
| Boehringer Ingelheim International GmbH | 1 | $430 |
| Grifols USA, LLC | 11 | $321 |
| Mylan Specialty L.p. | 9 | $263 |
| Genentech USA, Inc. | 9 | $234 |
| Pulmonx Corporation | 3 | $230 |
| Actelion Pharmaceuticals US, Inc. | 12 | $226 |
| Inari Medical, Inc. | 1 | $197 |
| Regeneron Healthcare Solutions, Inc. | 4 | $161 |
| ZOLL Respicardia, Inc. | 1 | $130 |
| Circassia Inc. | 8 | $126 |
| Sanofi | 7 | $124 |
| United Therapeutics Corporation | 1 | $120 |
| Verona Pharma, Inc. | 1 | $109 |
| La Jolla Pharmaceutical Company | 1 | $97 |
| Stryker | 3 | $75 |
| Itamar Medical Inc | 1 | $71 |
| CSL Behring | 4 | $66 |
| Amgen | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $51 |
| Philips North America LLC | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Melinta Therapeutics, LLC | 2 | $35 |
| Phadia US Inc. | 2 | $35 |
| Mayne Pharma Commercial LLC | 2 | $33 |
| Viatris Specialty LLC | 1 | $27 |
| Electromed, Inc. | 2 | $24 |
| Monaghan Medical Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Harmony Biosciences LLC | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$6,585
- TEZSPIRE$723
- FLOWTRIEVER CATHETER, S$393
- NUCALA$238
- ANORO$235
- SPIRIVA RESPIMAT$203
- Prolastin-C Liquid$158
- Arikayce$137
- remede System$130
- Yupelri$120
- AIRSUPRA$120
- AREXVY$120
- CHARTIS CATHETER$116
- ZEPHYR DELIVERY CATHETER$116
- ZEPHYR ENDOBRONCHIAL VALVE$116
- PULMONX CHARTIS TABLET CONSOLE$116
- Ohtuvayre$109
- OFEV$101
How this compares
$15,357 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 404 | $318,058 |
| Dupixent PenDupilumab | 46 | $179,544 |
| OfevNintedanib Esylate | 11 | $139,687 |
| Spiriva RespimatTiotropium Bromide | 62 | $60,685 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $44,744 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $40,242 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $35,293 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $26,747 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $18,564 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 71 | $14,178 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 89 | $11,767 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $9,909 |
| Spiriva HandihalerTiotropium Bromide | 11 | $9,405 |
| Arnuity ElliptaFluticasone Furoate | 31 | $7,915 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,193 | $417,023628 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $8,414 | $227,118120 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,873 | $53,85898 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.